Filing Details
- Accession Number:
- 0001209191-19-016941
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-03-05 18:21:06
- Reporting Period:
- 2019-03-01
- Accepted Time:
- 2019-03-05 18:21:06
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1714899 | Denali Therapeutics Inc. | DNLI | Biological Products, (No Disgnostic Substances) (2836) | 463872213 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1724605 | Carole Ho | C/O Denali Therapeutics Inc. 151 Oyster Point Boulevard, Second Floor South San Francisco CA 94080 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-03-01 | 5,775 | $5.28 | 5,775 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-03-01 | 3,824 | $22.17 | 1,951 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-03-01 | 1,951 | $22.92 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2019-03-04 | 5,863 | $5.28 | 5,863 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-03-04 | 4,263 | $21.87 | 1,600 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-03-04 | 1,600 | $22.84 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2019-03-05 | 5,862 | $5.28 | 5,862 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-03-05 | 5,862 | $21.96 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2019-03-01 | 5,775 | $0.00 | 5,775 | $5.28 |
| Common Stock | Stock Option (right to buy) | Disposition | 2019-03-04 | 5,863 | $0.00 | 5,863 | $5.28 |
| Common Stock | Stock Option (right to buy) | Disposition | 2019-03-05 | 5,862 | $0.00 | 5,862 | $5.28 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 123,855 | 2027-03-07 | No | 4 | M | Direct | |
| 117,992 | 2027-03-07 | No | 4 | M | Direct | |
| 112,130 | 2027-03-07 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 46,875 | Direct | |
| Common Stock | 25,000 | Indirect | See footnote |
| Common Stock | 142,615 | Indirect | See footnote |
Footnotes
- The shares are held of record by Carole Ho and Rajat Rohatgi.
- The shares are held of record by the Rohatgi-Ho Irrevocable GST Trust, for which Reporting Person serves as trustee.
- The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
- The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $21.78 to $22.72 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $22.82 to $23.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $21.54 to $22.27 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $22.61 to $23.17 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $21.51 to $22.32 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- Of the total 187,500 shares granted, 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter.
Billionaire Hedge Funds
